Guidant, Boston Scientific Stocks Weather DES Issues
This article was originally published in The Gray Sheet
Executive Summary
Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May
You may also be interested in...
Guidant Strengthens Resolve To Build Vulnerable Plaque Market
Guidant is backing its previously stated pledge to develop a market for the diagnosis and treatment of vulnerable plaque, investing in Miravant Medical Technologies' PhotoPoint photodynamic therapy
Guidant Champion Stent Design Flaw Delays Marketing By Up To Eight Months
A European launch of Guidant's Champion everolimus drug-eluting stent will require no additional clinical data, despite needed design and manufacturing changes, the firm says
Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing